

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1123R1D1C1	Serial No. 10/791,619
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Lowman et al.		
		Filing Date 3/2/04	Group 1644	

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
	* 1 4,255,519	10.03.81	Terada et al.	—	—	—
	* 2 4,275,149	23.06.81	Litman et al.	—	—	—
	* 3 4,816,567	28.03.89	Cabilly et al.	—	—	—
	* 4 5,534,617	09.07.96	Cunningham et al.	—	—	—
	* 5 5,561,053	01.10.96	Crowley	—	—	—
	* 6 5,622,700	22.04.97	Jardieu et al.	—	—	—
	* 7 5,705,154	06.01.98	Dalie et al.	—	—	—
	* 8 5,750,373	12.05.98	Garrard et al.	—	—	—
	* 9 5,821,337	13.10.98	Carter et al.	—	—	—
	* 10 5,965,709	12.10.99	Presta et al.	—	—	—
	* 11 5,994,511	30.11.99	Lowman et al	—	—	—
	* 12 6,037,453	14.03.00	Jardieu et al.	—	—	—
	* 13 6,054,297	25.04.00	Carter et al.	—	—	—
	* 14 6,329,509	11.12.01	Jardieu et al.	—	—	—
	* 15 6,407,213	18.06.02	Carter et al.	—	—	—

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
	* 16 239,400B1	03.08.94	EPO	—	—	
	* 17 93/11161	10.06.93	PCT	—	—	
	18 WO 92/17207	15.10.92	PCT	—	—	
	* 19 WO 93/04173	04.03.93	PCT	—	—	
	* 20 WO 93/16185	19.08.93	PCT	—	—	
	21 WO 94/20533	15.09.94	PCT	—	—	
	* 22 WO 95/24481	14.09.95	PCT	—	—	
	* 23 WO 97/06822	27.02.97	PCT	—	—	

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


	* 24	Alberts et al., "The Immune System" <u>Molecular Biology of The Cell</u> , 3d edition, New York and London:Garland Publishing, Inc., Chapter 23, pps. G-15 and 1232 (1994).
	* 25	Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution" <u>Science</u> 233:747-753 (Aug 1986)
	* 26	Barbas III et al., "In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity." <u>Proc. Natl. Acad. Sci. USA</u> 91(9):3809-3813 (Apr 26, 1994)
	* 27	Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments" <u>Science</u> 229:81-83 (July 1985)
	* 28	Cacia et al., "Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity" <u>Biochemistry</u> 35(6):1897-1903 (Feb 13, 1996)

Examiner



Date Considered

6/20/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1123RID1C1	Serial No. 10/791,619
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Lowman et al.		
		Filing Date 3/2/04	Group 1644	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
*29	Carter et al., "High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment." <u>Bio/Technology</u> , 10(2):163-167 (Feb 1992)			
*30	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)			
*31	Champe et al., "Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a" <u>Journal of Biological Chemistry</u> 270:1388-1394 (1995)			
*32	Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins" <u>J. Mol. Biol</u> 196:901-917 (1987)			
*33	Chothia et al., "Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains" <u>Journal of Molecular Biology</u> 186:651-663 (1985)			
*34	Chothia, C. et al., "Conformations of immunoglobulin hypervariable regions" <u>Nature</u> 342(6252):877-883 (1989)			
*35	Clackson et al., "Making Antibody Fragments Using Phage Display Libraries" <u>Nature</u> 352:624-628 (1991)			
*36	Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991)			
*37	Cunningham et al., "Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor" <u>EMBO Journal</u> 13(11):2508-2515 (1994)			
*38	Geiger and Clarke, "Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation" <u>Journal of Biological Chemistry</u> 262(2):785-794 (Jan 15, 1987)			
*39	Goding, J.W., "Conjugation of antibodies with fluorochromes: modifications to the standard methods" <u>Journal of Immunological Methods</u> 13(3-4):215-226 (1976)			
*40	Hakimi et al., "The α subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding" <u>Journal of Biological Chemistry</u> 265(36):22079-22081 (1990)			
*41	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" <u>J. Mol. Biol.</u> 226:889-896 (1992)			
*42	Herbert et al. <u>Dictionary of Immunology</u> , 3rd edition, Blackwell Scientific Publications pps. 77 (1985)			
*43	Holliger et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments." <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)			
*44	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." <u>Nature</u> , 321:522-525 (May 29, 1986)			
*45	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , Bethesda, MD:National Institute of Health (1987)			
*46	Kabat <u>Sequences of Proteins of Immunological Interest</u> (Fourth Ed.), 4th edition pps. 41-42, 167-168 (1987)			
*47	Kabat <u>Sequences of Proteins of Immunological Interest</u> (pgs. 662-663, 671-672, 680-681, 697, 701-702, 710, 719-720, 2275-2276), 5th edition'1 (1991)			
*48	Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation" <u>Protein Engineering</u> 4(7):773-783 (1991)			
Examiner 			Date Considered 6/20/05	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and NOT considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1123R1D1C1	Serial No. 10/791,619
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Lowman et al.		
		Filing Date 3/2/04	Group 1644	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
*49	Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity." <u>Nature</u> . 256:495-497 (August 7, 1975)			
*50	Konig et al., "Chemical and Biological Properties of Porcine Secretin and Secretin Analogues Modified in Positions 3 and 4" <u>Gastroenterology</u> 72:797-800 (1977)			
*51	Kunkel et al., "Efficient site-directed mutagenesis using uracil-containing DNA" <u>Methods in Enzymology</u> 204:125-139 (1991)			
*52	Lowe et al., "Allergen-induced Histamine Release in Rat Mast Cells Transfected with the α Subunits of Fc ϵ RI" <u>J. Immunological Methods</u> 184:113-122 (1995)			
*53	Lowenson and Clarke, "Identification of isoaspartyl-containing sequences in peptides and proteins that are unusually poor substrates for the class II protein carboxyl methyltransferase" <u>Journal of Biological Chemistry</u> 265(6):3106-3110 (Feb 25, 1990)			
*54	Lowman and Wells, "Affinity Maturation of Human Growth Hormone by Monovalent Phage Display" <u>J. Mol. Biol.</u> 234:564-578 (1993)			
*55	Lowman et al., "Selecting High-Affinity Binding Proteins by Monovalent Phage Display" <u>Biochemistry</u> 30(45):10832-10838 (1991)			
*56	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" <u>Bio/Technology</u> 10:779-783 (1992)			
*57	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)			
*58	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)			
59	Metzger and Kinet, "How Antibodies Work: Focus on Fc Receptors" <u>FASEB J</u> 2(1):3-11 (January 1988)			
*60	Morimoto et al., "Single-step purification of F(ab') ₂ fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW" <u>Journal of Biochemical and Biophysical Methods</u> 24:107-117 (1992)			
*61	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)			
*62	Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers" <u>Proc. Natl. Acad. Sci. USA</u> 82(14):4592-4596 (Jul 1985)			
*63	Oliyai and Borchardt, "Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide" <u>Pharmaceutical Research</u> 10(1):95-102 (Jan 1993)			
*64	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)			
*65	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)			
*66	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)			
*67	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)			
*68	Routledge et al., "A Humanized Monovalent CD3 Antibody which Can Activate Homologous Complement" <u>European Journal of Immunology</u> 21:2717-2725 (1991)			
Examiner 			Date Considered 6/20/05	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1123R1D1C1	Serial No. 10/791,619
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Lowman et al.		
		Filing Date 3/2/04	Group 1644	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
*69	Shearman et al., "Construction, Expression and Characterization of Humanized Antibodies Directed Against the Human α/β T Cell Receptor" <u>J. Immunol.</u> 147(12):4366-4373 (December 15, 1991)			
*70	Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995)			
*71	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)			
*72	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)			
*73	Tempest et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo" <u>Bio/Technology</u> 9:266-271 (March 1991)			
*74	Tutt et al., "Trispecific F(ab')3 Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells" <u>J. Immunol.</u> 147(1):60-69 (1991)			
*75	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)			
*76	Waterhouse et al., "Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires" <u>Nucleic Acids Research</u> 21:2265-2266 (1993)			
*77	Yang et al., "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range" <u>Journal of Molecular Biology</u> 254(3):392-403 (Dec 1, 1995)			
Examiner			Date Considered	
<p>*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				